Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Mate

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Cell Chemical Biology|August 1, 2023
Catalytic inhibitor of Protein Phosphatase 5 activates the extrinsic apoptotic pathway by disrupting complex II in kidney cancerElham F Ahanin, Rebecca A Sager, Sarah J Backe, et al.
Bioorganic & Medicinal Chemistry Letters|October 11, 2012
2-(N-Benzyl-N-phenylsulfonamido)alkyl amide derivatives as γ-secretase inhibitorsMichael F Parker, Donna M Barten, Carl P Bergstrom, et al.
Bioorganic & Medicinal Chemistry Letters|February 8, 2017
Design and synthesis of a novel series of 4-heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes as α7 nicotinic receptor agonists 2. Development of 4-heteroaryl SARChristiana Iwuagwu, Dalton King, Ivar M McDonald, et al.
Journal of Medicinal Chemistry|August 1, 2014
Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacyKin Sing Stephen Lee, Jun-Yan Liu, Karen M Wagner, et al.
Journal of Medicinal Chemistry|April 28, 2018
Correction to Optimized Inhibitors of Soluble Epoxide Hydrolase Improve in Vitro Target Residence Time and in Vivo EfficacyKin Sing Stephen Lee, Jun-Yan Liu, Karen M Wagner, et al.
ACS Medicinal Chemistry Letters|January 21, 2017
Development of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes] as α7 Nicotinic Receptor AgonistsMatthew D Hill, Haiquan Fang, H Dalton King, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase InhibitorKevin W Gillman, John E Starrett, Michael F Parker, et al.
Journal of Medicinal Chemistry|December 14, 2016
Design and Synthesis of a New Series of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes as α7 Nicotinic Receptor Agonists. 1. Development of Pharmacophore and Early Structure-Activity RelationshipJames Cook, F Christopher Zusi, Ivar M McDonald, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Cell Chemical Biology|August 1, 2023
Catalytic inhibitor of Protein Phosphatase 5 activates the extrinsic apoptotic pathway by disrupting complex II in kidney cancerElham F Ahanin, Rebecca A Sager, Sarah J Backe, et al.
Bioorganic & Medicinal Chemistry Letters|October 11, 2012
2-(N-Benzyl-N-phenylsulfonamido)alkyl amide derivatives as γ-secretase inhibitorsMichael F Parker, Donna M Barten, Carl P Bergstrom, et al.
Bioorganic & Medicinal Chemistry Letters|February 8, 2017
Design and synthesis of a novel series of 4-heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes as α7 nicotinic receptor agonists 2. Development of 4-heteroaryl SARChristiana Iwuagwu, Dalton King, Ivar M McDonald, et al.
Journal of Medicinal Chemistry|August 1, 2014
Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacyKin Sing Stephen Lee, Jun-Yan Liu, Karen M Wagner, et al.
Journal of Medicinal Chemistry|April 28, 2018
Correction to Optimized Inhibitors of Soluble Epoxide Hydrolase Improve in Vitro Target Residence Time and in Vivo EfficacyKin Sing Stephen Lee, Jun-Yan Liu, Karen M Wagner, et al.
ACS Medicinal Chemistry Letters|January 21, 2017
Development of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes] as α7 Nicotinic Receptor AgonistsMatthew D Hill, Haiquan Fang, H Dalton King, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase InhibitorKevin W Gillman, John E Starrett, Michael F Parker, et al.
Journal of Medicinal Chemistry|December 14, 2016
Design and Synthesis of a New Series of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes as α7 Nicotinic Receptor Agonists. 1. Development of Pharmacophore and Early Structure-Activity RelationshipJames Cook, F Christopher Zusi, Ivar M McDonald, et al.
Pageof 6